Iconovo AB (publ) (ICO.ST)
SEK 4.17
(-2.11%)
SEK 4.17
(-2.11%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.07 Million SEK | -58.65% |
| 2022 | 17.11 Million SEK | 11.08% |
| 2021 | 15.4 Million SEK | -13.39% |
| 2020 | 17.79 Million SEK | 51.58% |
| 2019 | 11.73 Million SEK | -1.43% |
| 2018 | 11.9 Million SEK | -40.67% |
| 2017 | 20.07 Million SEK | 39.61% |
| 2016 | 14.37 Million SEK | 9504.07% |
| 2015 | 149.69 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | - SEK | -100.0% |
| 2024 Q1 | 1.7 Million SEK | 75.62% |
| 2024 Q2 | 7.29 Million SEK | 328.82% |
| 2023 FY | 7.07 Million SEK | -58.65% |
| 2023 Q4 | 968 Thousand SEK | -69.57% |
| 2023 Q3 | 3.18 Million SEK | 21.37% |
| 2023 Q2 | 2.62 Million SEK | 748.22% |
| 2023 Q1 | 309 Thousand SEK | 804.43% |
| 2022 Q2 | 7.11 Million SEK | 157.09% |
| 2022 FY | 17.11 Million SEK | 11.08% |
| 2022 Q4 | 34.16 Thousand SEK | -99.53% |
| 2022 Q3 | 7.2 Million SEK | 1.32% |
| 2022 Q1 | 2.76 Million SEK | -23.17% |
| 2021 FY | 15.4 Million SEK | -13.39% |
| 2021 Q3 | 6.16 Million SEK | 76.46% |
| 2021 Q2 | 3.49 Million SEK | 62.98% |
| 2021 Q4 | 3.6 Million SEK | -41.64% |
| 2021 Q1 | 2.14 Million SEK | -72.07% |
| 2020 Q4 | 7.68 Million SEK | 33.48% |
| 2020 Q3 | 5.75 Million SEK | 137.28% |
| 2020 Q2 | 2.42 Million SEK | 25.52% |
| 2020 FY | 17.79 Million SEK | 51.58% |
| 2020 Q1 | 1.93 Million SEK | 2445469.62% |
| 2019 Q4 | 79.00 SEK | -100.0% |
| 2019 Q3 | 3.47 Million SEK | 14.73% |
| 2019 Q2 | 3.02 Million SEK | -42.17% |
| 2019 Q1 | 5.23 Million SEK | 17.99% |
| 2019 FY | 11.73 Million SEK | -1.43% |
| 2018 Q4 | 4.43 Million SEK | 315.92% |
| 2018 Q2 | 5.46 Million SEK | 483.35% |
| 2018 Q1 | 937 Thousand SEK | -92.23% |
| 2018 FY | 11.9 Million SEK | -40.67% |
| 2018 Q3 | 1.06 Million SEK | -80.48% |
| 2017 Q4 | 12.06 Million SEK | 4925.42% |
| 2017 Q3 | 240 Thousand SEK | -96.91% |
| 2017 Q2 | 7.77 Million SEK | 857.02% |
| 2017 FY | 20.07 Million SEK | 39.61% |
| 2017 Q1 | 812 Thousand SEK | 0.0% |
| 2016 FY | 14.37 Million SEK | 9504.07% |
| 2015 FY | 149.69 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -13.416% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.484% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.484% |
| Arcoma AB | 163.01 Million SEK | 95.658% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 96.53% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.684% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 98.761% |
| CellaVision AB (publ) | 677.29 Million SEK | 98.955% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | 14.441% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -625.026% |
| C-Rad AB (publ) | 424.61 Million SEK | 98.333% |
| Duearity AB (publ) | 1.65 Million SEK | -327.95% |
| Dignitana AB (publ) | 86.06 Million SEK | 91.775% |
| Episurf Medical AB (publ) | 10.3 Million SEK | 31.279% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.978% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Integrum AB (publ) | 104.11 Million SEK | 93.202% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -728.161% |
| Mentice AB (publ) | 273.61 Million SEK | 97.413% |
| OssDsign AB (publ) | 112.15 Million SEK | 93.689% |
| Paxman AB (publ) | 210.11 Million SEK | 96.631% |
| Promimic AB (publ) | 37.07 Million SEK | 80.906% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -2800.938% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 69.549% |
| ScandiDos AB (publ) | 60.42 Million SEK | 88.287% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.761% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 95.4% |
| Senzime AB (publ) | 35.75 Million SEK | 80.203% |
| SpectraCure AB (publ) | 318 Thousand SEK | -2125.877% |
| Stille AB | 294.89 Million SEK | 97.6% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.798% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 98.815% |